查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1534371

非何傑金氏淋巴瘤治療市場：全球規模、佔有率、趨勢分析、機會、預測，2019-2030

Non-Hodgkin Lymphoma Therapeutics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Therapy Type; By Drug Class; By Route of Administration; By End User; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2030年全球非何傑金氏淋巴瘤治療市場規模將達205億美元

由於非何杰金氏淋巴瘤盛行率的上升、老年人口的擴大以及生物技術進步的迅速採用，全球非何傑金氏淋巴瘤治療市場正在迅速擴大。

領先的策略諮詢和市場研究公司 BlueWeave Consulting 在最近的一項研究中估計，2023 年全球非何傑金氏淋巴瘤治療市場規模以金額為準123 億美元。 BlueWeave預測，2024年至2030年的預測期內，全球非何傑金氏淋巴瘤治療市場規模將以8.90%的複合年成長率成長，到2023年達到205億美元。全球非何傑金氏淋巴瘤治療市場是由發病率上升、診斷技術進步以及包括標靶治療和免疫療法在內的創新療法的市場發展所推動的。醫療保健支出的增加、早期診斷意識的提高以及政府的支持措施也促進了市場的成長。此外，全球人口老化、免疫力缺乏疾病日益普及以及製藥公司對研發的大量投資也進一步推動了市場擴張。總之，這些因素增加了非何傑金氏淋巴瘤患者治療選擇的可用性和有效性。

機會－新藥聯合治療的開發

創新藥物聯合治療正在徹底改變非何傑金氏淋巴瘤(NHL) 治療並推動市場擴張。這些聯合治療通常將標靶治療與傳統化療或免疫療法結合起來，提高療效，同時最大限度地減少副作用。隨著個人化治療方法的進步，製藥公司正在大力投資研發，以確定協同效應藥物對並最佳化治療方法。此外，精準醫療和生物標記主導治療的出現進一步強化了這一趨勢，為不同的非何傑金氏淋巴瘤亞型提供了量身定做的解決方案。因此，市場正在加速成長，有望改善結果和改善患者照護。

地緣政治緊張局勢加劇對全球非何傑金氏淋巴瘤治療市場的影響

地緣政治緊張局勢的加劇對全球非何傑金氏淋巴瘤治療市場產生重大影響。俄羅斯-烏克蘭戰爭等衝突造成的供應鏈中斷可能會減緩藥品的生產和分配。貿易限制和製裁阻礙了基本原料和藥品的取得。例如，COVID-19 大流行加劇了這些問題，並凸顯了全球供應鏈的脆弱性。此外，國防支出的增加可能會轉移醫療保健資金並影響研發投資。地緣政治不穩定造成的不確定性也會導致市場狀況波動，進而影響投資者信心和新治療方法的資金籌措。因此，維持穩定的地緣政治環境對於確保淋巴瘤治療的持續進展和可用性至關重要。

全球非何傑金氏淋巴瘤治療市場

按細分市場分類的覆蓋範圍

非何傑金氏淋巴瘤治療的全球市場 – 按給藥途徑分類

根據給藥途徑，全球非何傑金氏淋巴瘤治療市場分為口服、靜脈注射、皮下注射和鞘內注射。在全球非何傑金氏淋巴瘤治療市場中，靜脈注射注射佔最大佔有率。這一優點歸因於靜脈注射療法在非何傑金氏淋巴瘤治療方案中的廣泛使用。靜脈注射可將藥物快速輸送到血流中，從而實現高效且有效的治療。新生物製藥和靜脈注射單株抗體的引入也推動了這一領域的成長，這些藥物已成為淋巴瘤治療的標準。這一趨勢預計將持續下去，該領域的市場主導地位將進一步加強。

競爭格局

全球非何傑金氏淋巴瘤治療市場競爭激烈。市場主要企業包括阿斯利康公司、拜耳公司、羅氏公司、葛蘭素史克公司、Seagen Inc.、武田製藥有限公司、楊森製藥公司、禮來公司、Spectrum Pharmaceuticals Inc.、百時美施貴寶公司和艾伯維。這些公司正在增加對研發活動、併購、聯盟、授權合約的投資，並發布新產品和服務，以進一步加強其在全球非何傑金氏淋巴瘤治療市場的地位。

該報告的詳細分析提供了有關全球非何傑金氏淋巴瘤治療市場的成長潛力、未來趨勢和統計數據的資訊。它還涵蓋了推動市場總規模預測的因素。該報告致力於提供全球非何傑金氏淋巴瘤治療市場的最新技術趨勢和產業見解，以幫助決策者做出明智的策略決策。此外，我們也分析了市場的成長動力、挑戰和競爭力。

目錄

第1章 研究框架

第 2 章執行摘要

第3章全球非何傑金氏淋巴瘤治療市場洞察

  • 產業價值鏈分析
  • DROC分析
    • 生長促進因子
      • 非何傑金氏淋巴瘤發生率上升
      • 擴大採用標靶治療和免疫療法
      • 人口老化加劇
    • 抑制因素
      • 治療費用上漲
      • 有限退費政策
      • 嚴格的監管核准流程
    • 機會
      • 新藥聯合治療的開發
      • 潛力開拓的新興市場
      • 個人化醫療日益受到關注
    • 任務
      • 復發/難治性病例的抗藥性
      • 與治療相關的副作用
      • 維持醫療保健系統的永續性
  • 科技進步/最新趨勢
  • 法律規範
  • 波特五力分析

第4章全球非何傑金氏淋巴瘤治療市場：行銷策略

第5章全球非何傑金氏淋巴瘤治療市場：價格分析

第6章全球非何傑金氏淋巴瘤治療市場：區域分析

  • 全球非何傑金氏淋巴瘤治療市場，區域分析，2023 年
  • 2024-2030年全球非何傑金氏淋巴瘤治療市場吸引力分析

第7章 全球非何傑金氏淋巴瘤治療市場概述

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按治療類型
      • 化療
      • 免疫療法
      • 標靶治療
      • 放射治療
      • 幹細胞移植
    • 按藥品類別
      • 單株抗體
      • 蛋白酪氨酸激酶抑制劑
      • 蛋白酶體抑制劑
      • 組蛋白去乙醯化酶抑制劑
      • 抗代謝物
    • 依給藥途徑
      • 口服
      • 靜脈
      • 皮下注射
      • 椎管內的
    • 按最終用戶
      • 醫院
      • 專科診所
      • 門診手術中心
      • 家庭護理設置
    • 按國家/地區
      • 北美洲
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲（中東/非洲）

第8章北美非何傑金氏淋巴瘤治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按治療類型
    • 按藥品類別
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
      • 美國
      • 加拿大

第9章歐洲非何傑金氏淋巴瘤治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按治療類型
    • 按藥物類別
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第10章亞太非何非何傑金氏淋巴瘤治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按治療類型
    • 按藥品類別
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳洲和紐西蘭
      • 印尼
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他國家

第11章拉丁美洲非何傑金氏淋巴瘤治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按治療類型
    • 按藥品類別
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 其他拉丁美洲

第12章中東與非洲非何傑金氏淋巴瘤治療市場

  • 2019-2030年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 按治療類型
    • 按藥物類別
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • 中東和非洲其他地區

第13章競爭格局

  • 主要企業及其驅動器類型列表
  • 2023年全球非何傑金氏淋巴瘤治療市場佔有率分析
  • 透過管理參數進行競爭基準化分析
  • 重大策略發展（合併、收購、聯盟等）

第14章全球非何傑金氏淋巴瘤治療市場：進出口

第15章地緣政治緊張局勢加劇對全球非何傑金氏淋巴瘤治療市場的影響

第16章 公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人員、主要競爭對手、聯絡方式、策略展望、SWOT分析）

  • AstraZeneca Plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • Janssen Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc.
  • Bristol Myers Squibb Co.
  • AbbVie
  • 其他主要企業

第17章 主要戰略建議

第18章調查方法

簡介目錄
Product Code: BWC24515

Global Non-Hodgkin Lymphoma Therapeutics Market Size to Touch Value of USD 20.5 Billion by 2030

Global Non-Hodgkin Lymphoma Therapeutics Market is expanding rapidly due to the rising prevalence of the disease, expanding geriatric population, and rapid adoption of advancements in biotechnology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Non-Hodgkin Lymphoma Therapeutics Market size by value at USD 12.3 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Non-Hodgkin Lymphoma Therapeutics Market size to expand at a CAGR of 8.90% reaching a value of USD 20.5 billion in 2023. Global Non-Hodgkin Lymphoma Therapeutics Market is driven by rising incidence rates of the disease, advancements in diagnostic techniques, and the development of innovative treatments, including targeted therapies and immunotherapies. Increased healthcare expenditure, growing awareness about early diagnosis, and supportive government initiatives also contribute to market growth. Additionally, an aging global population, a higher prevalence of immunodeficiency disorders, and significant investments in research and development by pharmaceutical companies further propel the market expansion. These factors collectively enhance the availability and efficacy of therapeutic options for patients with non-Hodgkin lymphoma.

Opportunity - Development of novel drug combinations

Innovative drug combinations are revolutionizing Non-Hodgkin Lymphoma (NHL) treatment, propelling market expansion. These combinations, often integrating targeted therapies with traditional chemotherapy or immunotherapy, enhance efficacy while minimizing adverse effects. With an increasingly personalized approach to treatment, pharmaceutical companies are investing heavily in research and development to identify synergistic drug pairs and optimize treatment regimens. Moreover, the emergence of precision medicine and biomarker-driven therapies further augments the trend, offering tailored solutions for different NHL subtypes. Consequently, the market witnesses accelerated growth, driven by the promise of improved outcomes and enhanced patient care.

Impact of Escalating Geopolitical Tensions on Global Non-Hodgkin Lymphoma Therapeutics Market

Escalating geopolitical tensions significantly impact Global Non-Hodgkin Lymphoma Therapeutics Market. Disruptions in the supply chain due to conflicts, such as the Russia-Ukraine war, can delay drug production and distribution. Trade restrictions and sanctions hinder the availability of essential raw materials and pharmaceuticals. For instance, the COVID-19 pandemic exacerbated these issues, highlighting the vulnerability of global supply chains. Additionally, increased defense spending can divert funds from healthcare, affecting research and development investments. The uncertainty caused by geopolitical instability may also lead to fluctuating market conditions, affecting investor confidence and funding for new therapies. Thus, maintaining a stable geopolitical environment is crucial for ensuring continuous advancements and availability in lymphoma treatments.

Global Non-Hodgkin Lymphoma Therapeutics Market

Segmental Coverage

Global Non-Hodgkin Lymphoma Therapeutics Market - By Route of Administration

Based on route of administration, Global Non-Hodgkin Lymphoma Therapeutics Market is divided into Oral, Intravenous, Subcutaneous, and Intrathecal segments. The intravenous segment holds the largest share in Global Non-Hodgkin Lymphoma Therapeutics Market. The dominance is due to the widespread use of intravenous therapies in the treatment protocols for non-Hodgkin lymphoma. Intravenous administration allows for rapid delivery of drugs into the bloodstream, ensuring efficient and effective treatment. The segment's growth is also driven by the introduction of new intravenous biologics and monoclonal antibodies, which have become standard in lymphoma care. The trend is expected to continue, reinforcing the segment's leading position in the market.

Competitive Landscape

Global Non-Hodgkin Lymphoma Therapeutics Market is fiercely competitive. Major companies in the market include AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Seagen Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc., Eli Lilly and Company, Spectrum Pharmaceuticals Inc., Bristol Myers Squibb Co., and AbbVie. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Non-Hodgkin Lymphoma Therapeutics Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Non-Hodgkin Lymphoma Therapeutics Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in Global Non-Hodgkin Lymphoma Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Therapy Type Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Non-Hodgkin Lymphoma Therapeutics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising Prevalence of Non-Hodgkin Lymphoma
      • 3.2.1.2. Increasing Adoption of Targeted Therapies and Immunotherapy
      • 3.2.1.3. Growing Geriatric Population
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of Treatments
      • 3.2.2.2. Limited Reimbursement Policies
      • 3.2.2.3. Stringent Regulatory Approval Process
    • 3.2.3. Opportunities
      • 3.2.3.1. Development of Novel Drug Combinations
      • 3.2.3.2. Emerging Markets with Untapped Potential
      • 3.2.3.3. Rising Focus on Personalized Medicine
    • 3.2.4. Challenges
      • 3.2.4.1. Drug Resistance in Relapsed/Refractory Cases
      • 3.2.4.2. Side Effects Associated with Therapies
      • 3.2.4.3. Maintaining Sustainability in Healthcare Systems
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Non-Hodgkin Lymphoma Therapeutics Market: Marketing Strategies

5. Global Non-Hodgkin Lymphoma Therapeutics Market: Pricing Analysis

6. Global Non-Hodgkin Lymphoma Therapeutics Market: Geography Analysis

  • 6.1. Global Non-Hodgkin Lymphoma Therapeutics Market, Geographical Analysis, 2023
  • 6.2. Global Non-Hodgkin Lymphoma Therapeutics Market Attractiveness Analysis, 2024-2030

7. Global Non-Hodgkin Lymphoma Therapeutics Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
      • 7.2.1.1. Chemotherapy
      • 7.2.1.2. Immunotherapy
      • 7.2.1.3. Targeted Therapy
      • 7.2.1.4. Radiation Therapy
      • 7.2.1.5. Stem Cell Transplantation
    • 7.2.2. By Drug Class
      • 7.2.2.1. Monoclonal Antibodies
      • 7.2.2.2. Tyrosine Kinase Inhibitors
      • 7.2.2.3. Proteasome Inhibitors
      • 7.2.2.4. Histone Deacetylase Inhibitors
      • 7.2.2.5. Antimetabolites
    • 7.2.3. By Route of Administration
      • 7.2.3.1. Oral
      • 7.2.3.2. Intravenous
      • 7.2.3.3. Subcutaneous
      • 7.2.3.4. Intrathecal
    • 7.2.4. By End User
      • 7.2.4.1. Hospitals
      • 7.2.4.2. Specialty Clinics
      • 7.2.4.3. Ambulatory Surgical Centers
      • 7.2.4.4. Homecare Settings
    • 7.2.5. By Country
      • 7.2.5.1. North America
      • 7.2.5.2. Europe
      • 7.2.5.3. Asia Pacific (APAC)
      • 7.2.5.4. Latin America (LATAM)
      • 7.2.5.5. Middle East and Africa (MEA)

8. North America Non-Hodgkin Lymphoma Therapeutics Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. United States
      • 8.2.5.1.1. By Therapy Type
      • 8.2.5.1.2. By Drug Class
      • 8.2.5.1.3. By Route of Administration
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Canada
      • 8.2.5.2.1. By Therapy Type
      • 8.2.5.2.2. By Drug Class
      • 8.2.5.2.3. By Route of Administration
      • 8.2.5.2.4. By End User

9. Europe Non-Hodgkin Lymphoma Therapeutics Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Germany
      • 9.2.5.1.1. By Therapy Type
      • 9.2.5.1.2. By Drug Class
      • 9.2.5.1.3. By Route of Administration
      • 9.2.5.1.4. By End User
      • 9.2.5.2. United Kingdom
      • 9.2.5.2.1. By Therapy Type
      • 9.2.5.2.2. By Drug Class
      • 9.2.5.2.3. By Route of Administration
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Italy
      • 9.2.5.3.1. By Therapy Type
      • 9.2.5.3.2. By Drug Class
      • 9.2.5.3.3. By Route of Administration
      • 9.2.5.3.4. By End User
      • 9.2.5.4. France
      • 9.2.5.4.1. By Therapy Type
      • 9.2.5.4.2. By Drug Class
      • 9.2.5.4.3. By Route of Administration
      • 9.2.5.4.4. By End User
      • 9.2.5.5. Spain
      • 9.2.5.5.1. By Therapy Type
      • 9.2.5.5.2. By Drug Class
      • 9.2.5.5.3. By Route of Administration
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Belgium
      • 9.2.5.6.1. By Therapy Type
      • 9.2.5.6.2. By Drug Class
      • 9.2.5.6.3. By Route of Administration
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Russia
      • 9.2.5.7.1. By Therapy Type
      • 9.2.5.7.2. By Drug Class
      • 9.2.5.7.3. By Route of Administration
      • 9.2.5.7.4. By End User
      • 9.2.5.8. The Netherlands
      • 9.2.5.8.1. By Therapy Type
      • 9.2.5.8.2. By Drug Class
      • 9.2.5.8.3. By Route of Administration
      • 9.2.5.8.4. By End User
      • 9.2.5.9. Rest of Europe
      • 9.2.5.9.1. By Therapy Type
      • 9.2.5.9.2. By Drug Class
      • 9.2.5.9.3. By Route of Administration
      • 9.2.5.9.4. By End User

10. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
      • 10.2.5.1. China
      • 10.2.5.1.1. By Therapy Type
      • 10.2.5.1.2. By Drug Class
      • 10.2.5.1.3. By Route of Administration
      • 10.2.5.1.4. By End User
      • 10.2.5.2. India
      • 10.2.5.2.1. By Therapy Type
      • 10.2.5.2.2. By Drug Class
      • 10.2.5.2.3. By Route of Administration
      • 10.2.5.2.4. By End User
      • 10.2.5.3. Japan
      • 10.2.5.3.1. By Therapy Type
      • 10.2.5.3.2. By Drug Class
      • 10.2.5.3.3. By Route of Administration
      • 10.2.5.3.4. By End User
      • 10.2.5.4. South Korea
      • 10.2.5.4.1. By Therapy Type
      • 10.2.5.4.2. By Drug Class
      • 10.2.5.4.3. By Route of Administration
      • 10.2.5.4.4. By End User
      • 10.2.5.5. Australia & New Zealand
      • 10.2.5.5.1. By Therapy Type
      • 10.2.5.5.2. By Drug Class
      • 10.2.5.5.3. By Route of Administration
      • 10.2.5.5.4. By End User
      • 10.2.5.6. Indonesia
      • 10.2.5.6.1. By Therapy Type
      • 10.2.5.6.2. By Drug Class
      • 10.2.5.6.3. By Route of Administration
      • 10.2.5.6.4. By End User
      • 10.2.5.7. Malaysia
      • 10.2.5.7.1. By Therapy Type
      • 10.2.5.7.2. By Drug Class
      • 10.2.5.7.3. By Route of Administration
      • 10.2.5.7.4. By End User
      • 10.2.5.8. Singapore
      • 10.2.5.8.1. By Therapy Type
      • 10.2.5.8.2. By Drug Class
      • 10.2.5.8.3. By Route of Administration
      • 10.2.5.8.4. By End User
      • 10.2.5.9. Vietnam
      • 10.2.5.9.1. By Therapy Type
      • 10.2.5.9.2. By Drug Class
      • 10.2.5.9.3. By Route of Administration
      • 10.2.5.9.4. By End User
      • 10.2.5.10. Rest of APAC
      • 10.2.5.10.1. By Therapy Type
      • 10.2.5.10.2. By Drug Class
      • 10.2.5.10.3. By Route of Administration
      • 10.2.5.10.4. By End User

11. Latin America Non-Hodgkin Lymphoma Therapeutics Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy Type
    • 11.2.2. By Drug Class
    • 11.2.3. By Route of Administration
    • 11.2.4. By End User
    • 11.2.5. By Country
      • 11.2.5.1. Brazil
      • 11.2.5.1.1. By Therapy Type
      • 11.2.5.1.2. By Drug Class
      • 11.2.5.1.3. By Route of Administration
      • 11.2.5.1.4. By End User
      • 11.2.5.2. Mexico
      • 11.2.5.2.1. By Therapy Type
      • 11.2.5.2.2. By Drug Class
      • 11.2.5.2.3. By Route of Administration
      • 11.2.5.2.4. By End User
      • 11.2.5.3. Argentina
      • 11.2.5.3.1. By Therapy Type
      • 11.2.5.3.2. By Drug Class
      • 11.2.5.3.3. By Route of Administration
      • 11.2.5.3.4. By End User
      • 11.2.5.4. Peru
      • 11.2.5.4.1. By Therapy Type
      • 11.2.5.4.2. By Drug Class
      • 11.2.5.4.3. By Route of Administration
      • 11.2.5.4.4. By End User
      • 11.2.5.5. Rest of LATAM
      • 11.2.5.5.1. By Therapy Type
      • 11.2.5.5.2. By Drug Class
      • 11.2.5.5.3. By Route of Administration
      • 11.2.5.5.4. By End User

12. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Therapy Type
    • 12.2.2. By Drug Class
    • 12.2.3. By Route of Administration
    • 12.2.4. By End User
    • 12.2.5. By Country
      • 12.2.5.1. Saudi Arabia
      • 12.2.5.1.1. By Therapy Type
      • 12.2.5.1.2. By Drug Class
      • 12.2.5.1.3. By Route of Administration
      • 12.2.5.1.4. By End User
      • 12.2.5.2. UAE
      • 12.2.5.2.1. By Therapy Type
      • 12.2.5.2.2. By Drug Class
      • 12.2.5.2.3. By Route of Administration
      • 12.2.5.2.4. By End User
      • 12.2.5.3. Qatar
      • 12.2.5.3.1. By Therapy Type
      • 12.2.5.3.2. By Drug Class
      • 12.2.5.3.3. By Route of Administration
      • 12.2.5.3.4. By End User
      • 12.2.5.4. Kuwait
      • 12.2.5.4.1. By Therapy Type
      • 12.2.5.4.2. By Drug Class
      • 12.2.5.4.3. By Route of Administration
      • 12.2.5.4.4. By End User
      • 12.2.5.5. South Africa
      • 12.2.5.5.1. By Therapy Type
      • 12.2.5.5.2. By Drug Class
      • 12.2.5.5.3. By Route of Administration
      • 12.2.5.5.4. By End User
      • 12.2.5.6. Nigeria
      • 12.2.5.6.1. By Therapy Type
      • 12.2.5.6.2. By Drug Class
      • 12.2.5.6.3. By Route of Administration
      • 12.2.5.6.4. By End User
      • 12.2.5.7. Algeria
      • 12.2.5.7.1. By Therapy Type
      • 12.2.5.7.2. By Drug Class
      • 12.2.5.7.3. By Route of Administration
      • 12.2.5.7.4. By End User
      • 12.2.5.8. Rest of MEA
      • 12.2.5.8.1. By Therapy Type
      • 12.2.5.8.2. By Drug Class
      • 12.2.5.8.3. By Route of Administration
      • 12.2.5.8.4. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Drive Types
  • 13.2. Global Non-Hodgkin Lymphoma Therapeutics Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Global Non-Hodgkin Lymphoma Therapeutics Market: Import & Export

15. Impact of Escalating Geopolitical Tensions on Global Non-Hodgkin Lymphoma Therapeutics Market

16. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 16.1. AstraZeneca Plc
  • 16.2. Bayer AG
  • 16.3. F. Hoffmann-La Roche Ltd
  • 16.4. GlaxoSmithKline Plc
  • 16.5. Seagen Inc.
  • 16.6. Takeda Pharmaceutical Company Limited
  • 16.7. Janssen Pharmaceuticals Inc.
  • 16.8. Eli Lilly and Company
  • 16.9. Spectrum Pharmaceuticals Inc.
  • 16.10. Bristol Myers Squibb Co.
  • 16.11. AbbVie
  • 16.12. Other Prominent Players

17. Key Strategic Recommendations

18. Research Methodology

  • 18.1. Qualitative Research
    • 18.1.1. Primary & Secondary Research
  • 18.2. Quantitative Research
  • 18.3. Market Breakdown & Data Triangulation
    • 18.3.1. Secondary Research
    • 18.3.2. Primary Research
  • 18.4. Breakdown of Primary Research Respondents, By Region
  • 18.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable